Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2011

View Archived Issues

New muscarinic acetylcholine M1 receptor modulators claimed

Roche discloses new modulators of metabotropic glutamate mGlu5 receptor

Novel MK2 inhibitors synthesized at Merck & Co.

SHARP trial assesses simvastatin/ezetimibe combination in chronic kidney disease

One-pot approach creates semihollow microgel capsules for simultaneous multidrug delivery

Peptide P-13 ameliorates experimental otitis media

Dehydro-alpha-lapachone is natural antiangiogenic product that targets cell adhesion

Newron Pharmaceuticals submits IND for NW-3509 in schizophrenia

Biotron begins dosing final patient in phase IIa BIT-225 trial in genotype 1 hepatitis C

Sanofi and Regeneron report phase IIb data on sarilumab

Novel PKB inhibitors presented

Eisai to market and distribute Orion's Fareston and Eldepryl in China

Treatment begins in Cerulean Pharma's phase II CRLX-101 study in NSCLC

High-dose EPIAO approved in China to treat chemotherapy-associated anemia

GE Healthcare presents novel diagnostic imaging agents

AnaptysBio selects new antibody with potential to treat autoimmune diseases

FDA accepts sNDA for Dacogen in acute myeloid leukemia

Novadex presents new agents for HBV and HIV infections

Istituto Europeo di Oncologia patents new tubulin polymerization inhibitors

DSMB recommends discontinuation of Stallergenes' phase III trial of Actair

BioAlliance gives update on Livatag and Clonidine Lauriad

CMX-001 enters phase II trial in adenoviral disease and receives FDA fast track status

Teva completes acquisition of Taiyo Pharmaceutical

Consortium led by Ark Therapeutics receives E.U. Framework Programme 7 Grant

Watson Pharmaceuticals and Antares sign licensing agreement for Anturol gel in U.S. and Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Heartbeam wins appeal, gains FDA clearance
BioWorld MedTech
Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...